StockIQ.techModerna Inc. (MRNA) Stock Analysis
Free AI-powered analysis and research for Moderna Inc. stock
Sector: Healthcare
MRNA snapshot
Data as of 9 Oct 2026 close. Updated daily.
Moderna Inc. scores 16/100 on StockIQ's model, which reads as strongly negative signals overall. The price is above its 200-day average and at 100% of its 52-week range, up 738.6% over the past year. Latest reported figures show a profit margin of -141.4%, return on equity of -39.0% and revenue growth of +2.1%.
What is driving the score
- RSI Overbought: -15
- Strong Uptrend: +12
- MACD Bearish: -8
- Unprofitable (-141.4%): -15
- Low Debt (0.19 D/E): +8
- Strong Liquidity (2.29 Current Ratio): +8
- Negative ROE (-39.0%): -10
- High P/B (11.65): -5
- Strong Long-term Uptrend: +8
- Extreme Overextension (+738.6% over 1 year): -15
- High Volume (1.6x): +3
- Near 52-Week High (100%): -5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full MRNA report
Moderna Inc. (MRNA) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze MRNA Now →📰 Latest Update
Moderna stock surges more than 600% in 2026
Mon, October 12, 2026 at 5:33 PM UTC 2 min read
Moderna's stock experienced a remarkable surge of over 600% in 2026, driven by the successful commercialization of its mRNA technology beyond COVID-19 vaccines, including treatments for various diseases. This significant increase highlights the company's potential for sustained growth and innovation in the biotech sector, making it an attractive investment opportunity. Investors should consider the implications of Moderna's expanding product pipeline and its ability to capitalize on its technological advancements.